Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor

被引:68
作者
Hiasa, K
Egashira, K
Kitamoto, S
Ishibashi, M
Inoue, S
Ni, WH
Zhao, QW
Nagata, S
Katoh, M
Sata, M
Takeshita, A
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan
[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka, Japan
[5] Tanabe Seiyaku Co Ltd, Discovery & Pharmacol Res Labs, Toda, Saitama, Japan
[6] Univ Tokyo, Grad Sch Med Sci, Dept Cardiovasc Med, Tokyo, Japan
关键词
cell therapy; myocardial infarction; vascular endothelial cell growth factor;
D O I
10.1007/s00395-004-0456-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
No prior study has examined the effect of intravenous injection of bone marrow mononuclear cells (MNCs) on myocardial infarction size (IS). We tested the hypothesis that transplantation of MNCs decreases IS through the release of vascular endothelial growth factor (VEGF). Immediately after ligation of the left coronary artery of immunodeficient mice, PBS or MNCs were intravenously administered. Myocardial IS was significantly less in MNCs-treated mice than in PBS-treated mice. Trace experiments showed accumulation of exogenously administered MNCs into the vicinity of infarcted myocardium. Injection of MNCs did not affect capillary density after infarction, but did reduced myocardial cell apoptosis. Blockade of VEGF by a neutralizing antibody or by gene transfer of a soluble form of Flt-1 VEGF receptor diminished the IS-limiting effects of MNCs. In conclusion, injection of MNCs can reduce myocardial IS through the release of VEGF. The MNC therapy for acute myocardial infarction might improve prognosis of patients with myocardial infarction.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 30 条
[1]   Isolation of putative progenitor endothelial cells for angiogenesis [J].
Asahara, T ;
Murohara, T ;
Sullivan, A ;
Silver, M ;
vanderZee, R ;
Li, T ;
Witzenbichler, B ;
Schatteman, G ;
Isner, JM .
SCIENCE, 1997, 275 (5302) :964-967
[2]   Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization [J].
Asahara, T ;
Masuda, H ;
Takahashi, T ;
Kalka, C ;
Pastore, C ;
Silver, M ;
Kearne, M ;
Magner, M ;
Isner, JM .
CIRCULATION RESEARCH, 1999, 85 (03) :221-228
[3]   An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo [J].
Asano, M ;
Yukita, A ;
Matsumoto, T ;
Hanatani, M ;
Suzuki, H .
HYBRIDOMA, 1998, 17 (02) :185-190
[4]   Increased ischemia-induced angiogenesis in the staggerer mouse, a mutant of the nuclear receptor Rorα [J].
Besnard, S ;
Silvestre, JS ;
Duriez, M ;
Bakouche, J ;
Lemaigre-Dubreuil, Y ;
Mariani, J ;
Levy, BI ;
Tedgui, A .
CIRCULATION RESEARCH, 2001, 89 (12) :1209-1215
[5]   Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI) -: Mechanistic insights from serial contrast-enhanced magnetic resonance imaging [J].
Britten, MB ;
Abolmaali, ND ;
Assmus, B ;
Lehmann, R ;
Honold, J ;
Schmitt, J ;
Vogl, TJ ;
Martin, H ;
Schächinger, V ;
Dimmeler, S ;
Zeiher, AM .
CIRCULATION, 2003, 108 (18) :2212-2218
[6]   CURRENT CONCEPTS - CARDIOGENIC-SHOCK [J].
CALIFF, RM ;
BENGTSON, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (24) :1724-1730
[7]   Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration [J].
Dimmeler, S ;
Dernbach, E ;
Zeiher, AM .
FEBS LETTERS, 2000, 477 (03) :258-262
[8]  
DIMMELER S, CIRC RES, V86, P4
[9]   Temporal trends in event rates after Q-wave myocardial infarction - The framingham heart study [J].
Guidry, UC ;
Evans, JC ;
Larson, MG ;
Wilson, PWF ;
Murabito, JM ;
Levy, D .
CIRCULATION, 1999, 100 (20) :2054-2059
[10]  
IANBA S, 2002, LANCET, V360, P2084